CTLA4 and small cell lung carcinoma: Combinations of PD-1 or CTLA-4 inhibitors with standard treatment have the potential to be first-line treatments for ED-SCLC,10 but the performance of immunotherapies as second-line or maintenance treatments has proven to be inadequate.11,12